Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Stock Competitors & Peer Comparison
See (TORNTPHARM.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TORNTPHARM.NS | ₹4,210.80 | +0.00% | 1.4T | 63.57 | ₹67.17 | +0.82% |
| SUNPHARMA.BO | ₹1,744.35 | +0.00% | 4.3T | 39.06 | ₹45.50 | +0.93% |
| SUNPHARMA.NS | ₹1,744.40 | +0.00% | 4.3T | 39.04 | ₹45.52 | +0.93% |
| DIVISLAB.BO | ₹5,977.60 | +0.00% | 1.6T | 65.44 | ₹93.25 | +0.49% |
| DIVISLAB.NS | ₹5,972.50 | +0.00% | 1.6T | 65.47 | ₹93.17 | +0.49% |
| TORNTPHARM.BO | ₹4,209.15 | +0.00% | 1.4T | 67.47 | ₹63.25 | +0.82% |
| DRREDDY.BO | ₹1,274.05 | +0.00% | 1.1T | 19.15 | ₹67.84 | +0.62% |
| DRREDDY.NS | ₹1,274.50 | +0.00% | 1.1T | 19.14 | ₹67.85 | +0.62% |
| LUPIN.NS | ₹2,251.50 | +0.00% | 1.1T | 22.92 | ₹101.32 | +0.52% |
| LUPIN.BO | ₹2,253.90 | +0.00% | 1.1T | 24.61 | ₹94.37 | +0.52% |
Stock Comparison
TORNTPHARM.NS vs SUNPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUNPHARMA.BO trades at ₹1,744.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUNPHARMA.BO's P/E ratio is 39.06. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUNPHARMA.BO's competition here
TORNTPHARM.NS vs SUNPHARMA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUNPHARMA.NS trades at ₹1,744.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUNPHARMA.NS's P/E ratio is 39.04. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUNPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUNPHARMA.NS's competition here
TORNTPHARM.NS vs DIVISLAB.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while DIVISLAB.BO trades at ₹5,977.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas DIVISLAB.BO's P/E ratio is 65.44. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to DIVISLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check DIVISLAB.BO's competition here
TORNTPHARM.NS vs DIVISLAB.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while DIVISLAB.NS trades at ₹5,972.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas DIVISLAB.NS's P/E ratio is 65.47. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to DIVISLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check DIVISLAB.NS's competition here
TORNTPHARM.NS vs TORNTPHARM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while TORNTPHARM.BO trades at ₹4,209.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas TORNTPHARM.BO's P/E ratio is 67.47. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, TORNTPHARM.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check TORNTPHARM.BO's competition here
TORNTPHARM.NS vs DRREDDY.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while DRREDDY.BO trades at ₹1,274.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas DRREDDY.BO's P/E ratio is 19.15. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to DRREDDY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check DRREDDY.BO's competition here
TORNTPHARM.NS vs DRREDDY.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while DRREDDY.NS trades at ₹1,274.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas DRREDDY.NS's P/E ratio is 19.14. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check DRREDDY.NS's competition here
TORNTPHARM.NS vs LUPIN.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while LUPIN.NS trades at ₹2,251.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas LUPIN.NS's P/E ratio is 22.92. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to LUPIN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check LUPIN.NS's competition here
TORNTPHARM.NS vs LUPIN.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while LUPIN.BO trades at ₹2,253.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas LUPIN.BO's P/E ratio is 24.61. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to LUPIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check LUPIN.BO's competition here
TORNTPHARM.NS vs ZYDUSLIFE.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ZYDUSLIFE.BO has a market cap of 896.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ZYDUSLIFE.BO trades at ₹876.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ZYDUSLIFE.BO's P/E ratio is 18.16. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ZYDUSLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ZYDUSLIFE.BO's competition here
TORNTPHARM.NS vs ZYDUSLIFE.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ZYDUSLIFE.NS has a market cap of 896.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ZYDUSLIFE.NS trades at ₹876.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ZYDUSLIFE.NS's P/E ratio is 18.16. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ZYDUSLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ZYDUSLIFE.NS's competition here
TORNTPHARM.NS vs MANKIND.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, MANKIND.NS has a market cap of 825.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while MANKIND.NS trades at ₹2,000.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas MANKIND.NS's P/E ratio is 46.39. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check MANKIND.NS's competition here
TORNTPHARM.NS vs MANKIND.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, MANKIND.BO has a market cap of 825.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while MANKIND.BO trades at ₹2,001.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas MANKIND.BO's P/E ratio is 46.40. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check MANKIND.BO's competition here
TORNTPHARM.NS vs AUROPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AUROPHARMA.BO has a market cap of 750B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AUROPHARMA.BO trades at ₹1,247.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AUROPHARMA.BO's P/E ratio is 21.93. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AUROPHARMA.BO's competition here
TORNTPHARM.NS vs AUROPHARMA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AUROPHARMA.NS has a market cap of 750B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AUROPHARMA.NS trades at ₹1,247.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AUROPHARMA.NS's P/E ratio is 21.52. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AUROPHARMA.NS's competition here
TORNTPHARM.NS vs ALKEM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ALKEM.BO has a market cap of 628.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ALKEM.BO trades at ₹5,240.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ALKEM.BO's P/E ratio is 26.54. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ALKEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ALKEM.BO's competition here
TORNTPHARM.NS vs ALKEM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ALKEM.NS has a market cap of 628.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ALKEM.NS trades at ₹5,240.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ALKEM.NS's P/E ratio is 26.54. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ALKEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ALKEM.NS's competition here
TORNTPHARM.NS vs GLENMARK.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GLENMARK.BO has a market cap of 615.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GLENMARK.BO trades at ₹2,098.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GLENMARK.BO's P/E ratio is 57.65. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GLENMARK.BO's competition here
TORNTPHARM.NS vs GLENMARK.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GLENMARK.NS has a market cap of 615.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GLENMARK.NS trades at ₹2,097.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GLENMARK.NS's P/E ratio is 57.64. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GLENMARK.NS's competition here
TORNTPHARM.NS vs LAURUSLABS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, LAURUSLABS.NS has a market cap of 532.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while LAURUSLABS.NS trades at ₹944.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas LAURUSLABS.NS's P/E ratio is 63.12. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check LAURUSLABS.NS's competition here
TORNTPHARM.NS vs LAURUSLABS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, LAURUSLABS.BO has a market cap of 532.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while LAURUSLABS.BO trades at ₹947.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas LAURUSLABS.BO's P/E ratio is 63.13. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check LAURUSLABS.BO's competition here
TORNTPHARM.NS vs SUVENPHAR.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUVENPHAR.NS's competition here
TORNTPHARM.NS vs SUVENPHAR.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUVENPHAR.BO's competition here
TORNTPHARM.NS vs IPCALAB.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, IPCALAB.BO has a market cap of 392.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while IPCALAB.BO trades at ₹1,545.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas IPCALAB.BO's P/E ratio is 43.05. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check IPCALAB.BO's competition here
TORNTPHARM.NS vs IPCALAB.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, IPCALAB.NS has a market cap of 391.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while IPCALAB.NS trades at ₹1,544.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas IPCALAB.NS's P/E ratio is 43.09. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check IPCALAB.NS's competition here
TORNTPHARM.NS vs AJANTPHARM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AJANTPHARM.NS has a market cap of 362.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AJANTPHARM.NS trades at ₹2,943.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AJANTPHARM.NS's P/E ratio is 35.75. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AJANTPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AJANTPHARM.NS's competition here
TORNTPHARM.NS vs AJANTPHARM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AJANTPHARM.BO has a market cap of 362.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AJANTPHARM.BO trades at ₹2,946.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AJANTPHARM.BO's P/E ratio is 35.81. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AJANTPHARM.BO's competition here
TORNTPHARM.NS vs JBCHEPHARM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, JBCHEPHARM.BO has a market cap of 346.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while JBCHEPHARM.BO trades at ₹2,085.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas JBCHEPHARM.BO's P/E ratio is 45.48. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check JBCHEPHARM.BO's competition here
TORNTPHARM.NS vs JBCHEPHARM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, JBCHEPHARM.NS has a market cap of 343.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while JBCHEPHARM.NS trades at ₹2,084.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas JBCHEPHARM.NS's P/E ratio is 45.08. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to JBCHEPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check JBCHEPHARM.NS's competition here
TORNTPHARM.NS vs EMCURE.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, EMCURE.NS has a market cap of 280.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while EMCURE.NS trades at ₹1,469.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas EMCURE.NS's P/E ratio is 32.21. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check EMCURE.NS's competition here
TORNTPHARM.NS vs PEL.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check PEL.NS's competition here
TORNTPHARM.NS vs ASTRAZEN.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ASTRAZEN.NS has a market cap of 208B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ASTRAZEN.NS trades at ₹8,370.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ASTRAZEN.NS's P/E ratio is 103.55. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ASTRAZEN.NS's competition here
TORNTPHARM.NS vs ASTRAZEN.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ASTRAZEN.BO has a market cap of 207.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ASTRAZEN.BO trades at ₹8,354.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ASTRAZEN.BO's P/E ratio is 103.55. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, TORNTPHARM.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ASTRAZEN.BO's competition here
TORNTPHARM.NS vs WOCKPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, WOCKPHARMA.BO has a market cap of 191.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while WOCKPHARMA.BO trades at ₹1,186.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas WOCKPHARMA.BO's P/E ratio is 878.28. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check WOCKPHARMA.BO's competition here
TORNTPHARM.NS vs WOCKPHARMA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, WOCKPHARMA.NS has a market cap of 191.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while WOCKPHARMA.NS trades at ₹1,187.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas WOCKPHARMA.NS's P/E ratio is 877.76. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check WOCKPHARMA.NS's competition here
TORNTPHARM.NS vs PPLPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, PPLPHARMA.BO has a market cap of 183B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while PPLPHARMA.BO trades at ₹135.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas PPLPHARMA.BO's P/E ratio is -111.49. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check PPLPHARMA.BO's competition here
TORNTPHARM.NS vs ERIS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ERIS.BO has a market cap of 178.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ERIS.BO trades at ₹1,282.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ERIS.BO's P/E ratio is 40.86. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ERIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ERIS.BO's competition here
TORNTPHARM.NS vs ERIS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ERIS.NS has a market cap of 178B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ERIS.NS trades at ₹1,286.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ERIS.NS's P/E ratio is 40.75. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ERIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ERIS.NS's competition here
TORNTPHARM.NS vs NATCOPHARM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, NATCOPHARM.NS has a market cap of 171.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while NATCOPHARM.NS trades at ₹938.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas NATCOPHARM.NS's P/E ratio is 11.03. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check NATCOPHARM.NS's competition here
TORNTPHARM.NS vs NATCOPHARM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, NATCOPHARM.BO has a market cap of 171.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while NATCOPHARM.BO trades at ₹937.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas NATCOPHARM.BO's P/E ratio is 11.15. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check NATCOPHARM.BO's competition here
TORNTPHARM.NS vs NEULANDLAB.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, NEULANDLAB.BO has a market cap of 154B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while NEULANDLAB.BO trades at ₹12,093.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas NEULANDLAB.BO's P/E ratio is 85.80. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check NEULANDLAB.BO's competition here
TORNTPHARM.NS vs NEULANDLAB.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, NEULANDLAB.NS has a market cap of 153.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while NEULANDLAB.NS trades at ₹12,101.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas NEULANDLAB.NS's P/E ratio is 85.73. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check NEULANDLAB.NS's competition here
TORNTPHARM.NS vs GRANULES.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GRANULES.NS has a market cap of 143.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GRANULES.NS trades at ₹582.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GRANULES.NS's P/E ratio is 26.28. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GRANULES.NS's competition here
TORNTPHARM.NS vs GRANULES.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GRANULES.BO has a market cap of 143.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GRANULES.BO trades at ₹582.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GRANULES.BO's P/E ratio is 26.27. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GRANULES.BO's competition here
TORNTPHARM.NS vs APLLTD.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, APLLTD.NS has a market cap of 133.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while APLLTD.NS trades at ₹655.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas APLLTD.NS's P/E ratio is 21.13. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to APLLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check APLLTD.NS's competition here
TORNTPHARM.NS vs APLLTD.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, APLLTD.BO has a market cap of 133.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while APLLTD.BO trades at ₹656.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas APLLTD.BO's P/E ratio is 21.14. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to APLLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check APLLTD.BO's competition here
TORNTPHARM.NS vs GLS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GLS.NS's competition here
TORNTPHARM.NS vs GLS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GLS.BO's competition here
TORNTPHARM.NS vs JUBLPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, JUBLPHARMA.BO has a market cap of 131.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while JUBLPHARMA.BO trades at ₹850.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas JUBLPHARMA.BO's P/E ratio is 30.57. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check JUBLPHARMA.BO's competition here
TORNTPHARM.NS vs JUBLPHARMA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, JUBLPHARMA.NS has a market cap of 131.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while JUBLPHARMA.NS trades at ₹850.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas JUBLPHARMA.NS's P/E ratio is 30.52. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check JUBLPHARMA.NS's competition here
TORNTPHARM.NS vs CAPLIPOINT.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, CAPLIPOINT.BO has a market cap of 121.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while CAPLIPOINT.BO trades at ₹1,621.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas CAPLIPOINT.BO's P/E ratio is 19.93. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check CAPLIPOINT.BO's competition here
TORNTPHARM.NS vs CAPLIPOINT.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, CAPLIPOINT.NS has a market cap of 121.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while CAPLIPOINT.NS trades at ₹1,621.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas CAPLIPOINT.NS's P/E ratio is 19.94. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check CAPLIPOINT.NS's competition here
TORNTPHARM.NS vs ALIVUS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ALIVUS.NS has a market cap of 116.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ALIVUS.NS trades at ₹926.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ALIVUS.NS's P/E ratio is 21.45. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ALIVUS.NS's competition here
TORNTPHARM.NS vs ALIVUS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ALIVUS.BO has a market cap of 116.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ALIVUS.BO trades at ₹926.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ALIVUS.BO's P/E ratio is 21.47. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ALIVUS.BO's competition here
TORNTPHARM.NS vs COHANCE.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, COHANCE.BO has a market cap of 114.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while COHANCE.BO trades at ₹299.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas COHANCE.BO's P/E ratio is 59.26. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check COHANCE.BO's competition here
TORNTPHARM.NS vs COHANCE.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, COHANCE.NS has a market cap of 114.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while COHANCE.NS trades at ₹299.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas COHANCE.NS's P/E ratio is 59.26. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check COHANCE.NS's competition here
TORNTPHARM.NS vs CAPPL.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check CAPPL.BO's competition here
TORNTPHARM.NS vs STAR.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, STAR.BO has a market cap of 83.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while STAR.BO trades at ₹897.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas STAR.BO's P/E ratio is 16.31. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check STAR.BO's competition here
TORNTPHARM.NS vs STAR.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, STAR.NS has a market cap of 83.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while STAR.NS trades at ₹897.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas STAR.NS's P/E ratio is 16.29. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check STAR.NS's competition here
TORNTPHARM.NS vs VIYASH.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, VIYASH.NS has a market cap of 82.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while VIYASH.NS trades at ₹189.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas VIYASH.NS's P/E ratio is 72.47. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check VIYASH.NS's competition here
TORNTPHARM.NS vs PGHL.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, PGHL.BO has a market cap of 80.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while PGHL.BO trades at ₹4,821.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas PGHL.BO's P/E ratio is 34.13. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to PGHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check PGHL.BO's competition here
TORNTPHARM.NS vs PGHL.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, PGHL.NS has a market cap of 80.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while PGHL.NS trades at ₹4,819.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas PGHL.NS's P/E ratio is 34.07. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to PGHL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check PGHL.NS's competition here
TORNTPHARM.NS vs AKUMS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AKUMS.NS has a market cap of 74B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AKUMS.NS trades at ₹468.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AKUMS.NS's P/E ratio is 23.11. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AKUMS.NS's competition here
TORNTPHARM.NS vs SHILPAMED.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SHILPAMED.NS has a market cap of 63.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SHILPAMED.NS trades at ₹314.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SHILPAMED.NS's P/E ratio is 28.61. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SHILPAMED.NS's competition here
TORNTPHARM.NS vs AARTIPHARM.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AARTIPHARM.BO has a market cap of 58.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AARTIPHARM.BO trades at ₹647.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AARTIPHARM.BO's P/E ratio is 27.34. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AARTIPHARM.BO's competition here
TORNTPHARM.NS vs AARTIPHARM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AARTIPHARM.NS has a market cap of 58.4B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AARTIPHARM.NS trades at ₹647.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AARTIPHARM.NS's P/E ratio is 27.37. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AARTIPHARM.NS's competition here
TORNTPHARM.NS vs FDC.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, FDC.BO has a market cap of 54.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while FDC.BO trades at ₹338.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas FDC.BO's P/E ratio is 25.05. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check FDC.BO's competition here
TORNTPHARM.NS vs FDC.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, FDC.NS has a market cap of 54.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while FDC.NS trades at ₹338.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas FDC.NS's P/E ratio is 25.01. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check FDC.NS's competition here
TORNTPHARM.NS vs SEQUENT.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SEQUENT.NS's competition here
TORNTPHARM.NS vs SEQUENT.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SEQUENT.BO's competition here
TORNTPHARM.NS vs INNOVACAP.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, INNOVACAP.NS has a market cap of 38.9B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while INNOVACAP.NS trades at ₹678.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas INNOVACAP.NS's P/E ratio is 29.39. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check INNOVACAP.NS's competition here
TORNTPHARM.NS vs SPARC.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SPARC.BO has a market cap of 37.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SPARC.BO trades at ₹115.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SPARC.BO's P/E ratio is -14.02. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SPARC.BO's competition here
TORNTPHARM.NS vs SPARC.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SPARC.NS has a market cap of 37.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SPARC.NS trades at ₹115.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SPARC.NS's P/E ratio is -13.99. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SPARC.NS's competition here
TORNTPHARM.NS vs SHILPAMED.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SHILPAMED.BO has a market cap of 31.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SHILPAMED.BO trades at ₹314.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SHILPAMED.BO's P/E ratio is 28.65. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SHILPAMED.BO's competition here
TORNTPHARM.NS vs AARTIDRUGS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AARTIDRUGS.BO has a market cap of 31.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AARTIDRUGS.BO trades at ₹337.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AARTIDRUGS.BO's P/E ratio is 15.54. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AARTIDRUGS.BO's competition here
TORNTPHARM.NS vs AARTIDRUGS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, AARTIDRUGS.NS has a market cap of 31.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while AARTIDRUGS.NS trades at ₹337.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas AARTIDRUGS.NS's P/E ratio is 15.52. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check AARTIDRUGS.NS's competition here
TORNTPHARM.NS vs SUVEN.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUVEN.NS has a market cap of 31.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUVEN.NS trades at ₹133.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUVEN.NS's P/E ratio is -10.88. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUVEN.NS's competition here
TORNTPHARM.NS vs RPGLIFE.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, RPGLIFE.NS has a market cap of 31.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while RPGLIFE.NS trades at ₹1,822.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas RPGLIFE.NS's P/E ratio is 15.35. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check RPGLIFE.NS's competition here
TORNTPHARM.NS vs RPGLIFE.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, RPGLIFE.BO has a market cap of 31.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while RPGLIFE.BO trades at ₹1,821.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas RPGLIFE.BO's P/E ratio is 15.33. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check RPGLIFE.BO's competition here
TORNTPHARM.NS vs SUVEN.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SUVEN.BO has a market cap of 31.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SUVEN.BO trades at ₹133.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SUVEN.BO's P/E ratio is -10.88. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SUVEN.BO's competition here
TORNTPHARM.NS vs GUJTHEM.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GUJTHEM.NS has a market cap of 29.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GUJTHEM.NS trades at ₹275.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GUJTHEM.NS's P/E ratio is 62.44. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GUJTHEM.NS's competition here
TORNTPHARM.NS vs GUFICBIO.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GUFICBIO.BO has a market cap of 29.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GUFICBIO.BO trades at ₹293.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GUFICBIO.BO's P/E ratio is 59.03. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GUFICBIO.BO's competition here
TORNTPHARM.NS vs GUFICBIO.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, GUFICBIO.NS has a market cap of 29.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while GUFICBIO.NS trades at ₹292.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas GUFICBIO.NS's P/E ratio is 58.87. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check GUFICBIO.NS's competition here
TORNTPHARM.NS vs ORCHPHARMA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ORCHPHARMA.BO has a market cap of 27.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ORCHPHARMA.BO trades at ₹516.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ORCHPHARMA.BO's P/E ratio is 142.28. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ORCHPHARMA.BO's competition here
TORNTPHARM.NS vs ORCHPHARMA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ORCHPHARMA.NS has a market cap of 27B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ORCHPHARMA.NS trades at ₹516.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ORCHPHARMA.NS's P/E ratio is 141.26. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ORCHPHARMA.NS's competition here
TORNTPHARM.NS vs NOVARTIND.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, NOVARTIND.BO has a market cap of 23.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while NOVARTIND.BO trades at ₹917.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas NOVARTIND.BO's P/E ratio is 23.72. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check NOVARTIND.BO's competition here
TORNTPHARM.NS vs BLISSGVS.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, BLISSGVS.BO has a market cap of 22.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while BLISSGVS.BO trades at ₹207.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas BLISSGVS.BO's P/E ratio is 20.70. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check BLISSGVS.BO's competition here
TORNTPHARM.NS vs BLISSGVS.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, BLISSGVS.NS has a market cap of 22.2B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while BLISSGVS.NS trades at ₹207.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas BLISSGVS.NS's P/E ratio is 20.63. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check BLISSGVS.NS's competition here
TORNTPHARM.NS vs UNICHEMLAB.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, UNICHEMLAB.NS has a market cap of 22.1B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while UNICHEMLAB.NS trades at ₹310.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas UNICHEMLAB.NS's P/E ratio is 7.50. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check UNICHEMLAB.NS's competition here
TORNTPHARM.NS vs UNICHEMLAB.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, UNICHEMLAB.BO has a market cap of 22B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while UNICHEMLAB.BO trades at ₹311.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas UNICHEMLAB.BO's P/E ratio is 7.49. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check UNICHEMLAB.BO's competition here
TORNTPHARM.NS vs IOLCP.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, IOLCP.NS has a market cap of 21.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while IOLCP.NS trades at ₹72.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas IOLCP.NS's P/E ratio is 18.83. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check IOLCP.NS's competition here
TORNTPHARM.NS vs IOLCP.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, IOLCP.BO has a market cap of 21.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while IOLCP.BO trades at ₹72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas IOLCP.BO's P/E ratio is 18.80. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check IOLCP.BO's competition here
TORNTPHARM.NS vs SOLARA.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SOLARA.NS has a market cap of 21.7B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SOLARA.NS trades at ₹448.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SOLARA.NS's P/E ratio is -93.79. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SOLARA.NS's competition here
TORNTPHARM.NS vs SOLARA.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, SOLARA.BO has a market cap of 21.6B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while SOLARA.BO trades at ₹448.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas SOLARA.BO's P/E ratio is -93.36. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check SOLARA.BO's competition here
TORNTPHARM.NS vs HIKAL.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, HIKAL.BO has a market cap of 20.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while HIKAL.BO trades at ₹166.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas HIKAL.BO's P/E ratio is 210.94. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check HIKAL.BO's competition here
TORNTPHARM.NS vs HIKAL.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, HIKAL.NS has a market cap of 20.8B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while HIKAL.NS trades at ₹165.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas HIKAL.NS's P/E ratio is -158.94. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check HIKAL.NS's competition here
TORNTPHARM.NS vs ALEMBICLTD.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, ALEMBICLTD.NS has a market cap of 20.5B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while ALEMBICLTD.NS trades at ₹78.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas ALEMBICLTD.NS's P/E ratio is 6.43. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check ALEMBICLTD.NS's competition here
TORNTPHARM.NS vs MOREPENLAB.BO Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, MOREPENLAB.BO has a market cap of 20.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while MOREPENLAB.BO trades at ₹37.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas MOREPENLAB.BO's P/E ratio is 20.68. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check MOREPENLAB.BO's competition here
TORNTPHARM.NS vs MOREPENLAB.NS Comparison March 2026
TORNTPHARM.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TORNTPHARM.NS stands at 1.4T. In comparison, MOREPENLAB.NS has a market cap of 20.3B. Regarding current trading prices, TORNTPHARM.NS is priced at ₹4,210.80, while MOREPENLAB.NS trades at ₹37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TORNTPHARM.NS currently has a P/E ratio of 63.57, whereas MOREPENLAB.NS's P/E ratio is 20.55. In terms of profitability, TORNTPHARM.NS's ROE is +0.29%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, TORNTPHARM.NS is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for TORNTPHARM.NS.Check MOREPENLAB.NS's competition here